FILE:PRGO/PRGO-8K-20080711080708.txt.gz
EVENTS:	Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
TEXT:
ITEM: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
 
 
Registrant's telephone number, including area code:
(269) 673-8451
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
 
                    ALLEGAN, Mich.- July 11, 2008  Perrigo Company (Nasdaq: PRGO; TASE) today announced that its Board of Directors has appointed Ellen R. Hoffing as a new director of the Company for a term expiring on the date of the 2009 annual meeting. Ms. Hoffing is not currently a member of any committee of the Board of Directors.
                    Since 2006, Ellen Hoffing, 51, has served as President and Chief Executive Officer of Applied NeuroSolutions, Inc., a development stage biopharmaceutical company focused on diagnostics and therapeutics for the treatment of Alzheimer's Disease. She has also served as Chairman of Applied NeuroSolutions' Board of Directors since December 2007. Ms. Hoffing has extensive experience in the pharmaceutical industry, including management, strategic planning and operations, given her prior senior positions at American Pharmaceutical Partners (2005  2006), Baxter Healthcare (2002-2005), and Searle Pharmaceuticals (1983  2000). Ms. Hoffing has a bachelor of science in accountancy from the University of Illinois at Urbana  Champaign and a masters in management from the Kellogg Graduate School of Management at Northwestern University.
     Ms. Hoffing will receive the directors' annual cash retainer and equity compensation, both pro-rated from the date she became a director.
 
Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


